<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of chronic graft-versus-host disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of chronic graft-versus-host disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of chronic graft-versus-host disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert Zeiser, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert S Negrin, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nelson J Chao, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Graft-versus-host disease (GVHD) can develop after allogeneic hematopoietic cell transplant (HCT), when immune cells from a non-identical donor (the graft) initiate an immune reaction against a transplant recipient (the host). Acute GVHD (aGVHD) and chronic GVHD (cGVHD) are multisystem disorders that are distinguished by their clinical findings, according to the widely-accepted National Institutes of Health (NIH) consensus criteria; an overlap syndrome with features of both aGVHD and cGVHD is also recognized [
         <a href="#rid1">
          1
         </a>
         ]. Formerly, aGVHD and cGVHD were distinguished by onset before or after 100 days from transplantation, but these syndromes may occur outside of those time periods.
        </p>
        <p>
         Clinical manifestations of cGVHD may be widespread or they may be restricted to a single organ or site. The primary manifestations of cGVHD are skin involvement resembling lichen planus or cutaneous scleroderma, dry oral mucosa, ulcerations and sclerosis of the gastrointestinal tract, elevated serum bilirubin, and bronchiolitis obliterans. By contrast, patients with aGVHD commonly demonstrate a maculopapular rash, abdominal cramps with diarrhea, and elevated serum bilirubin.
        </p>
        <p>
         cGVHD is a major cause of morbidity and mortality after allogeneic HCT, which worsen with disease severity. Patients have impaired physical, social, and psychological well-being and impaired quality of life. More than one-third of patients who undergo allogeneic HCT require systemic treatment for severe cGVHD [
         <a href="#rid2">
          2
         </a>
         ]. Treatment should aim to balance the benefit of reducing cGVHD against treatment-related adverse effects and potential diminution of a graft-versus-tumor effect.
        </p>
        <p>
         This topic discusses the treatment of cGVHD.
        </p>
        <p>
         Clinical manifestations, diagnosis, and grading of cGVHD are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">
          "Clinical manifestations and diagnosis of chronic graft-versus-host disease"
         </a>
         .)
        </p>
        <p>
         Related topics include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">
          "Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3543.html" rel="external">
          "Treatment of acute graft-versus-host disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3542.html" rel="external">
          "Prevention of graft-versus-host disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/122403.html" rel="external">
          "Survival, quality of life, and late complications after hematopoietic cell transplantation in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3545.html" rel="external">
          "Pathogenesis of graft-versus-host disease (GVHD)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H192889378">
         <span class="h1">
          PRETREATMENT EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pretreatment evaluation of cGVHD includes assessing which organ systems are affected and documenting the extent and severity of involvement. We use the National Institutes of Health (NIH) criteria for diagnosing and scoring the severity of cGVHD [
         <a href="#rid3">
          3
         </a>
         ], as described separately. Overall severity of cGVHD should be recorded.
        </p>
        <p>
         Details of clinical manifestations, evaluation, diagnosis, grading, and differential diagnosis of cGVHD are described separately. (See
         <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">
          "Clinical manifestations and diagnosis of chronic graft-versus-host disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2508166520">
         <span class="h2">
          Clinical and laboratory studies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical
         </strong>
         – History and physical examination should evaluate manifestations of cGVHD and the extent and severity of involvement  (
         <a class="graphic graphic_form graphicRef69017" href="/z/d/graphic/69017.html" rel="external">
          form 1
         </a>
         ). Comorbid conditions and medications taken for GVHD prophylaxis and treatment should be documented.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinical evaluation should assess:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Skin
         </strong>
         – Specific cutaneous features (eg, sclerosis, plaques, altered pigmentation)
         <strong>
          and
         </strong>
         the extent of involvement (ie, estimated body surface area [BSA])
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mouth
         </strong>
         – Lichen planus-like features
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Eyes, hair, nails
         </strong>
         – Dry eyes, alopecia, brittle nails
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Lungs
         </strong>
         – Dyspnea, fatigue, cough
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Gastrointestinal (GI) tract
         </strong>
         – Anorexia, nausea, ulceration, diarrhea
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Musculoskeletal
         </strong>
         – Weakness, arthralgias, arthritis, muscle cramps, joint contractures
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinical manifestations are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">
          "Clinical manifestations and diagnosis of chronic graft-versus-host disease", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Performance status
         </strong>
         <strong>
          (PS)
         </strong>
         – We score patients according to the Eastern Cooperative Oncology Group (ECOG) PS or Karnofsky PS  (
         <a class="graphic graphic_table graphicRef57945" href="/z/d/graphic/57945.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Complete blood count (CBC)
         </strong>
         with differential
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Chemistries
         </strong>
         – Serum electrolytes, glucose, renal function tests
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Liver function tests
         </strong>
         – Serum alkaline phosphatase, bilirubin, transaminases
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging
         </strong>
         – Imaging should include a chest radiograph and other imaging studies, as guided by clinical manifestations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other testing
         </strong>
         – Patients with cough, dyspnea, or other respiratory manifestations should undergo pulmonary function testing.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3895052758">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Importantly, cGVHD must be distinguished from the late onset of acute GVHD (aGVHD) and from overlap syndrome (simultaneous presence of aGVHD with diagnostic or distinctive features of cGVHD).
        </p>
        <p>
         Diagnostic criteria for cGVHD and distinctive features that distinguish it from aGVHD are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">
          "Clinical manifestations and diagnosis of chronic graft-versus-host disease", section on 'Diagnostic criteria'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H192889385">
         <span class="h2">
          Grading
         </span>
         <span class="headingEndMark">
          —
         </span>
         The severity of cGVHD should be graded to assess prognosis and guide management.
        </p>
        <p>
         We use a modification of the National Institutes of Health (NIH) scoring system, which includes assessment of skin, mouth, eyes, GI tract, liver, lungs, joints/fascia, and genital tract and grades the severity of affected organs from 0 to 3 (higher scores reflecting more severe disease)  (
         <a class="graphic graphic_form graphicRef69017" href="/z/d/graphic/69017.html" rel="external">
          form 1
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. Our grading differs in that we include &lt;100,000 platelets/microL as an additional criterion for severe disease.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild disease
         </strong>
         – Involvement of one or two organs
         <strong>
         </strong>
         with
         <strong>
         </strong>
         score ≤1
         <strong>
          plus
         </strong>
         lung score 0 and no significant functional impairment (eg, ECOG PS ≤2)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Moderate disease
         </strong>
         (any of the following):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Involvement of ≥3 organs with score ≤1
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lung score 1
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Any non-lung organ score 2
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Functional impairment (eg, ECOG PS ≥3)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe disease
         </strong>
         (any of the following):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lung score ≥2
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Any non-lung score 3
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Platelet count &lt;100,000/microL
        </p>
        <p>
        </p>
        <p>
         Details of the NIH scoring system and other grading systems are described separately. (See
         <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">
          "Clinical manifestations and diagnosis of chronic graft-versus-host disease", section on 'Prognosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2610700554">
         <span class="h1">
          GOALS OF TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goals of treatment are to produce a sustained reduction or elimination of symptom burden, disability, and disease activity, while limiting treatment-related adverse effects and enabling withdrawal of therapy without recurrence of cGVHD.
        </p>
        <p class="headingAnchor" id="H836344180">
         <span class="h1">
          INITIAL MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial treatment is guided by the classification of cGVHD as mild, moderate, or severe disease  (
         <a class="graphic graphic_algorithm graphicRef132572" href="/z/d/graphic/132572.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Grading'
         </a>
         above.)
        </p>
        <p>
         Optimal management requires a multidisciplinary team that includes transplant specialists, a primary care provider, organ-specific consultants, nurses, and ancillary services (eg, social services, vocational specialists, patient/family support groups).
        </p>
        <p>
         Our approach to management of cGVHD is consistent with guidelines from the American Society of Transplantation and Cell Therapy (ASTCT; formerly ASBMT) [
         <a href="#rid4">
          4
         </a>
         ], the British Committee for Standards in Hematology and the British Society for Bone Marrow Transplantation [
         <a href="#rid5">
          5,6
         </a>
         ], and the European Group for Blood and Marrow Transplantation (EBMT) and European LeukemiaNet [
         <a href="#rid7">
          7
         </a>
         ]. We encourage enrollment in a clinical trial, when possible.
        </p>
        <p class="headingAnchor" id="H3488722264">
         <span class="h2">
          Mild cGVHD
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with mild cGVHD, we suggest localized/topical treatment rather than systemic therapy, to avoid the adverse effects and complications of systemic glucocorticoids and/or other immunosuppressive agents.
        </p>
        <p>
         Localized/topical treatments for affected organs are described below. (See
         <a class="local">
          'Localized/topical treatments'
         </a>
         below.)
        </p>
        <p>
         In some cases of very widespread mild cGVHD (eg, skin involvement involving &gt;50 percent body surface area), systemic therapy may be favored by the clinician or patient, despite the toxicity and potential complications of oral glucocorticoids or other immunosuppressive agents. (See
         <a class="local">
          'Moderate cGVHD'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3018492880">
         <span class="h2">
          Moderate cGVHD
         </span>
         <span class="headingEndMark">
          —
         </span>
         For initial treatment of moderate cGVHD, we recommend systemic
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , rather than an alternative immunosuppressive agent, either alone or together with prednisone. Prednisone has been the standard of care for moderate or severe cGVHD for decades, based on observational studies that showed improved survival and performance status compared with outcomes prior to the routine use of prednisone [
         <a href="#rid8">
          8-11
         </a>
         ]. Prednisone has not been directly compared with other immunosuppressive agents, but addition of
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         , or
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         to prednisone did not improve the response rate, shorten the duration of therapy, or substantially reduce toxicity compared with prednisone alone, based on randomized trials [
         <a href="#rid8">
          8,11-15
         </a>
         ]. (See
         <a class="local">
          'Prednisone'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         is effective in nearly half of patients with moderate or severe cGVHD. However, treatment is typically protracted and associated with significant adverse effects. We seek to adjust the dose to avoid complications of chronic prednisone therapy, as described below. (See
         <a class="local">
          'Dose adjustment'
         </a>
         below.)
        </p>
        <p>
         Topical therapy can be added to systemic
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , if needed, to ameliorate localized symptoms. (See
         <a class="local">
          'Localized/topical treatments'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3232178892">
         <span class="h2">
          Severe cGVHD
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with severe cGVHD, we suggest initial treatment with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         plus
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         , rather than prednisone alone or prednisone plus an alternative second agent. This suggestion is based on expert opinion according to outcomes with prednisone plus ruxolitinib for patients with steroid-refractory (SR)-cGVHD. Some experts favor prednisone alone, as it has not been proven that ruxolitinib or any other second agent improves the response of severe cGVHD or substantially reduces adverse effects of prednisone, compared with prednisone alone, as described below. (See
         <a class="local">
          'Steroid-refractory (SR) cGVHD'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          Ruxolitinib
         </a>
         is not approved for initial treatment of cGVHD by the US Food and Drug Administration (FDA) or European Medicines Agency.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         plus
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         was not more effective than prednisone plus placebo in a double-blind, phase 3 trial (iNTEGRATE) of 193 patients (≥12 years) with previously-untreated moderate or severe cGVHD [
         <a href="#rid16">
          16
         </a>
         ]. Response rates were similar at 48 weeks (41 percent with prednisone-ibrutinib versus 37 percent with prednisone-placebo) and at 96 weeks (27 versus 22 percent, respectively); complete responses at 48 weeks (9 versus 6 percent) and at 96 weeks (14 versus 9 percent) were also similar. Overall survival, event-free survival, duration of response, and symptomatic improvement (based on Lee Symptom Scale [
         <a href="#rid17">
          17
         </a>
         ]) also did not differ significantly, but there was a trend toward greater withdrawal of all immunosuppressants in the prednisone-ibrutinib group than the prednisone-placebo group (47 percent versus 39 percent, respectively). Grade ≥3 adverse events occurred in approximately one-half of patients in both trial arms and no new safety signals emerged.
        </p>
        <p>
         If
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         is not available, contraindicated (eg, for platelets &lt;10,000/microL), not tolerated, or not available, we favor extracorporeal photopheresis (ECP; where available) as an effective non-pharmacologic approach to limit additional adverse effects. Otherwise, no second agent (other than ruxolitinib) is proven better than others. Selection of an alternative second agent is informed by current medications, toxicity, comorbid conditions, availability, and preferences of the clinician and patient.
        </p>
        <p class="headingAnchor" id="H2506998979">
         <span class="h2">
          Overlap syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with overlap syndrome have cGVHD with pre-existent acute GVHD (aGVHD). As a result, patients with overlap syndrome may already be receiving
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         therapy, with or without a calcineurin inhibitor (CI), for the aGVHD.
        </p>
        <p>
         Treatment of overlap syndrome is informed by the severity of the cGVHD, as described above (see
         <a class="local">
          'Initial management'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild manifestations of GVHD
         </strong>
         – (See
         <a class="local">
          'Mild cGVHD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Moderate cGVHD
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          No current systemic
         </strong>
         <strong>
          prednisone
         </strong>
         – Treat with systemic
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         . (See
         <a class="local">
          'Moderate cGVHD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Current systemic
         </strong>
         <strong>
          prednisone
         </strong>
         – Adjust the
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose (if lower than the suggested initial dose) (see
         <a class="local">
          'Dose adjustment'
         </a>
         below) or add a second agent to prednisone, as per severe cGVHD. (See
         <a class="local">
          'Severe cGVHD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Current
         </strong>
         <strong>
          prednisone
         </strong>
         <strong>
          plus a second agent
         </strong>
         – Treat as SR-cGVHD. (See
         <a class="local">
          'Treatment of SR-cGVHD'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe cGVHD
         </strong>
         – Treat with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         plus a second agent, as per SR-cGVHD. (See
         <a class="local">
          'Treatment of SR-cGVHD'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1820155102">
         <span class="h1">
          TREATMENTS
         </span>
        </p>
        <p class="headingAnchor" id="H313454710">
         <span class="h2">
          Localized/topical treatments
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management is guided by the involved organs, severity of findings, and response to treatment.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild cGVHD
         </strong>
         – Localized or topical treatments are usually sufficient for treatment of mild cGVHD. We adjust the treatment, as guided by the response and consider systemic therapy if there is progression to moderate of severe disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Moderate or severe cGVHD
         </strong>
         – Adding localized treatments to systemic therapy for patients who present with moderate or severe cGVHD can accelerate the response, improve local control, and/or reduce the dose and duration of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and other systemic agents with little or no additional toxicity.
        </p>
        <p>
        </p>
        <p>
         Detailed suggestions regarding organ-specific treatments have been provided by the American Society for Blood and Marrow Transplantation, the British Committee for Standards in Hematology, the British Society for Bone Marrow Transplantation, and the German-Austrian-Swiss Consensus Conference, and the European Society for Blood and Marrow Transplantation [
         <a href="#rid4">
          4,6,7,18-20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1375282060">
         <span class="h3">
          Skin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin is affected in two-thirds of patients with cGVHD.
         <strong>
         </strong>
         Maculopapular rash/erythema, dryness, and flaking are common with mild cutaneous involvement, while lichen planus and/or sclerosis are characteristic manifestations of grade ≥3 skin involvement. Thinning of the skin can make it prone to ulceration, while sclerosis can impair healing of the skin. (See
         <a class="medical medical_review" href="/z/d/html/13760.html" rel="external">
          "Cutaneous manifestations of graft-versus-host disease (GVHD)", section on 'Ancillary measures in chronic graft-versus-host disease'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptom relief
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Emollients
         </strong>
         – Ointments and creams are frequently used for relief with mild skin involvement.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Topical therapy
         </strong>
         – Topical glucocorticoids or calcineurin inhibitors should be used as first-line therapy for drying and flaking skin [
         <a href="#rid7">
          7
         </a>
         ]. Attention to areas of skin breakdown is important to ensure that these sites do not become secondarily infected.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Extracorporeal photopheresis (ECP)
         </strong>
         can be used for treatment of very extensive (eg, &gt;50 percent body surface area) skin involvement or when topical agents are not sufficient. (See
         <a class="local">
          'Extracorporeal photopheresis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Physical therapy
         </strong>
         may be useful for patients with sclerodermatous disease to prevent contractures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surveillance
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Referral to a dermatologist with experience in transplant dermatology is useful for patients with moderate or severe cutaneous GVHD.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Because of the increased risk of cutaneous malignancy, all patients on prolonged immunosuppression should have an annual skin check by a dermatologist.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         All growing/non-healing skin lesions should be referred to a dermatologist within two to four weeks.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3892435996">
         <span class="h3">
          Mouth
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptoms include inflammation, ulceration, and lichen planus-like lesions; when severe, symptoms may limit oral intake. (See
         <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">
          "Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Oral health'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptom relief
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hydration
         </strong>
         – Patients may carry a bottle of water and drink frequently; some may find relief with
         <a class="drug drug_general" data-topicid="8793" href="/z/d/drug information/8793.html" rel="external">
          artificial saliva
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Topical therapies
         </strong>
         – Steroid mouthwashes can be helpful in areas of ulceration or leukoplakia. Infection with
         <em>
          Herpes simplex
         </em>
         , human papilloma virus, and
         <em>
          Candida
         </em>
         and other fungal organisms should be ruled out before initiating topical steroids.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For oral lesions that do not respond adequately to topical agents, ECP can be used as systemic therapy. (See
         <a class="local">
          'Extracorporeal photopheresis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention/surveillance
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hygiene
         </strong>
         – Good oral/dental hygiene and topical fluorides to prevent caries are important [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Stretching
         </strong>
         exercises may increase the range of motion of the mouth.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Persistent or new oral lesions that occur &gt;3 months after transplantation should be evaluated for a secondary cancer.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4039755926">
         <span class="h3">
          Eyes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dry eyes are irritating and may progress to photophobia, pain, or impaired vision with severe disease [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         Initial evaluation and periodic follow-up by an ophthalmologist knowledgeable in the potential complications of transplantation is described separately. (See
         <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">
          "Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Ocular complications'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptom relief
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hydration
         </strong>
         – Preservative-free
         <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">
          artificial tears
         </a>
         , steroid eyedrops, and/or topical
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         can improve eye hydration [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Sunglasses
         </strong>
         can be helpful for photophobia.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In severe cases, gas-permeable scleral lenses may decrease symptoms. For patients who produce tears, tear duct plugs or permanent duct closure with laser treatment may lessen symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention/surveillance
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Symptoms suggestive of significant ocular involvement should be evaluated and managed by an ophthalmologist experienced with ocular GVHD. Clinicians should have a high degree of suspicion for infections (eg, infectious keratitis).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients on prolonged systemic steroids for cGVHD are at increased risk for developing cataracts.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H508796871">
         <span class="h3">
          Vagina
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vulvovaginal dryness and/or dyspareunia is a common problem, especially in the setting of estrogen insufficiency; ulcers, lichen planus-like features, vaginal stenosis, or complete obliteration may occur with progressive GVHD. All patients should be asked about sexual function. Additional discussion of the management of vulvovaginal atrophy, pain, and stenosis is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/5443.html" rel="external">
          "Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment", section on 'Vaginal estrogen therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/141056.html" rel="external">
          "Vulvar lichen sclerosus: Management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptom relief
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Topical therapy
         </strong>
         to the vaginal epithelium, using a dilator, if needed, include one or more of the following [
         <a href="#rid20">
          20,24,25
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Estrogen
         </strong>
         – Topical estrogens  (
         <a class="graphic graphic_table graphicRef58506" href="/z/d/graphic/58506.html" rel="external">
          table 2
         </a>
         ) can increase epithelial thickness and are typically prescribed daily for two weeks, followed by twice-weekly maintenance therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Corticosteroids
         </strong>
         – Topical steroids (eg, a pea-sized amount of
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          clobetasol
         </a>
         0.05% ointment) can be applied to the affected area twice daily for 6 to 12 weeks, followed by two to three times per week. Alternatively, 10 percent
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         rectal foam, inserted vaginally, can be used.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Antibiotics
         </strong>
         – Topical antibiotics (eg,
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         2% gel applied intravaginally for two weeks, then twice-weekly as maintenance therapy) can decrease inflammation.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Topical immunomodulators
         </strong>
         – Calcineurin inhibitors (eg,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">
          pimecrolimus
         </a>
         ) can be applied twice daily, with tapering over six weeks to achieve twice-weekly maintenance.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prevention
         </strong>
         – Early consultation with a gynecologist experienced in GVHD is helpful for management and to minimize disease progression.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Hygiene
         </strong>
         – Avoidance of lotions, soaps, and tight clothing should be encouraged.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         We perform gynecologic exams every three to six months for the first two years, and then as clinically indicated; photodocumentation may be useful to objectively monitor response.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4291371936">
         <span class="h3">
          Gastrointestinal
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nausea, vomiting, and dysphagia can progress to diarrhea with weight loss and/or esophageal web or stricture, when severe.
        </p>
        <p>
         Referral to a gastroenterologist should be considered for patients with suspected gastrointestinal (GI) cGVHD. All patients with GI GVHD or malnutrition should be assessed by a dietician.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptom relief
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Diarrhea
         </strong>
         – Evaluation should include cultures, testing
         <em>
         </em>
         for
         <em>
          Clostridioides difficile
         </em>
         toxin, and cytomegalovirus. Diarrhea without associated jaundice or rash suggestive of GVHD should be investigated by upper endoscopy (with duodenal aspirate and biopsies) and flexible sigmoidoscopy or colonoscopy (with biopsy).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Occasionally, patients may have persistent diarrhea/steatorrhea due to pancreatic insufficiency from cGVHD.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mechanical dilation (eg, bougienage) may be used to break apart the strictures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nutritional supplements can prevent weight loss.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pancreatic replacement is beneficial in this setting. (See
         <a class="medical medical_review" href="/z/d/html/5647.html" rel="external">
          "Chronic pancreatitis: Management", section on 'Management of pancreatic insufficiency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1863010026">
         <span class="h3">
          Lungs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evaluation and management of
         <strong>
         </strong>
         pulmonary manifestations of cGVHD, including supplemental oxygen, bronchodilators, inhaled corticosteroids, and pulmonary rehabilitation programs [
         <a href="#rid18">
          18
         </a>
         ] is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">
          "Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H57595729">
         <span class="h3">
          Musculoskeletal
         </span>
         <span class="headingEndMark">
          —
         </span>
         Erythema from myositis
         <strong>
         </strong>
         may be accompanied by limb swelling, muscle atrophy, weakness, and joint contractures [
         <a href="#rid19">
          19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">
          "Clinical manifestations and diagnosis of chronic graft-versus-host disease", section on 'Musculoskeletal'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptom relief
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Physical and/or occupational therapy
         </strong>
         may be helpful for patients with impaired activities of daily living. Repeated evaluation may be needed to assess muscular weakness and range of motion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients require screening for glucocorticoid-induced myopathy and sclerotic changes in the skin and fascia that can limit joint mobility.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Evaluation and management of accelerated bone loss is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">
          "Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Bone and joint health'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3606601836">
         <span class="h3">
          Endocrine
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is increased risk of diabetes mellitus, hypothyroidism, hypogonadism, and hypoadrenalism in cGVHD, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">
          "Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Diabetes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">
          "Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Other endocrine'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1591039772">
         <span class="h1">
          PREDNISONE
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         (or an equivalent systemic glucocorticoid) has long been preferred as initial systemic therapy for moderate or severe cGVHD. Because of adverse effects and complications of prolonged prednisone therapy, attention should be paid to adjusting the dose to the minimum amount needed to control symptoms  (
         <a class="graphic graphic_table graphicRef91020" href="/z/d/graphic/91020.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2112001598">
         <span class="h2">
          Initial dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         is usually started at 1 mg/kg/day. Use of higher doses of prednisone did not improve outcomes [
         <a href="#rid26">
          26
         </a>
         ] and no studies have directly tested whether every other day dosing would achieve comparable efficacy or reduce toxicity in this setting [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         The
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose should be adjusted according to symptomatic response and objective measures of GVHD [
         <a href="#rid28">
          28
         </a>
         ], as described below. (See
         <a class="local">
          'Dose adjustment'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adverse effects
         </strong>
         – Long-term
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         therapy is associated with infections, myopathy, avascular necrosis, osteoporosis, glucose intolerance, weight gain/altered body habitus, hypertension, cutaneous atrophy and striae, cataracts, emotional lability, sleep interference, and growth retardation in children. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prevention of infections
         </strong>
         – Patients who undergo allogeneic hematopoietic cell transplantation (HCT) are at risk for bacterial, viral, and fungal infections, which may be exacerbated by cytopenias, glucocorticoid therapy, and organ damage related to cGVHD. The time course of infections varies according to the degree of immune deficiency, cytopenias, time after transplantation, and
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         treatment, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1403.html" rel="external">
          "Overview of infections following hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Infection prophylaxis
         </strong>
         may include neutropenic precautions; antibacterial, antiviral, and antifungal drugs; and immunoglobulin infusions, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16534.html" rel="external">
          "Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1397.html" rel="external">
          "Prevention of infections in hematopoietic cell transplant recipients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Vaccination
         </strong>
         – All patients should be vaccinated against pneumococcus, influenza and
         <em>
          Haemophilus influenzae.
         </em>
         Importantly, live vaccines must
         <strong>
          not
         </strong>
         be administered to patients with cGVHD. (See
         <a class="medical medical_review" href="/z/d/html/3882.html" rel="external">
          "Immunizations in hematopoietic cell transplant candidates and recipients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – Approximately half of patients with cGVHD treated with systemic
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         have resolution of disease manifestations that enables tapering and later discontinuation of systemic therapy. Prednisone and
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         yield similar outcomes with cGVHD, based on phase 3 trials and various prospective and retrospective studies [
         <a href="#rid11">
          11,27,29-31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Outcomes with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         plus a second agent are presented below. (See
         <a class="local">
          'Treatment of SR-cGVHD'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H459546628">
         <span class="h2">
          Dose adjustment
         </span>
         <span class="headingEndMark">
          —
         </span>
         We promptly adjust the dose of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         to the minimum amount needed to control symptoms. We evaluate the patient after the first two weeks of prednisone and adjust the dose as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Improving cGVHD
         </strong>
         – For patients with a complete response (CR) or a good partial response (PR) after two weeks of therapy,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         can be tapered by 25 percent per week. The taper should continue until the dose reaches 0.10 mg/kg every other day; it can be discontinued after ≥4 weeks of treatment at that dose. For patients who have recurrent symptoms at this dose, treatment with very low prednisone doses may be required for a year or more.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If there is an exacerbation or recurrence of cGVHD at any step of the taper, the dose of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         should be increased promptly. It should be increased by two levels or returned to full-dose for two to four weeks, followed by resumption of alternate-day administration. Treatment should then be continued for at least three months before attempting to resume the taper.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stable or worsening findings
         </strong>
         – If there is no improvement after two weeks of full initial dose, we add a second agent, as described for steroid-refractory (SR)-cGVHD below. (See
         <a class="local">
          'Treatment of SR-cGVHD'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1274217004">
         <span class="h1">
          RESPONSE ASSESSMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         We assess response to localized and systemic treatment using the National Institutes of Health (NIH) Consensus Criteria for Clinical Trials in cGVHD [
         <a href="#rid32">
          32
         </a>
         ]. The NIH criteria can be applied to both adults and children and are practical for use by transplantation and non-transplantation clinicians. Forms for data collection are available on the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.astct.org%2Fhome&amp;token=j%2BtF41plvYHq0KcVLVNCgjydI%2FUZECjbq0OAPDgqzRENTO%2F7eHYXh5D7YvCErqQZ&amp;TOPIC_ID=3550" target="_blank">
          ASBMT website
         </a>
         [
         <a href="#rid33">
          33
         </a>
         ]. Provisional definitions of complete response (CR), partial response (PR), and disease progression are described for each organ system and for overall outcomes. There are no generally-accepted biomarkers for response in cGVHD.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Schedule
         </strong>
         – The schedule for response assessment is individualized according to disease severity, treatment(s), and concerns of the clinician and patient:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We initially assess the response to
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         after two weeks of therapy to determine if dose reduction is possible, as described above. (See
         <a class="local">
          'Dose adjustment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We reassess response at three-month intervals, when there are major changes in symptoms or treatment, and according to concerns by the patient or clinicians.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         of response should include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Interval history and examination
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Laboratory studies:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Complete blood count (CBC) with differential
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Serum electrolytes, glucose, and liver and renal function tests
        </p>
        <p>
        </p>
        <p>
         The NIH response criteria have been validated in a prospective cGVHD observational study [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1724793108">
         <span class="h1">
          STEROID-REFRACTORY (SR) cGVHD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately half of patients with cGVHD become steroid-refractory (SR), which greatly increases the risk of poor outcomes [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3876248448">
         <span class="h2">
          Definition of SR-cGVHD
         </span>
         <span class="headingEndMark">
          —
         </span>
         SR-cGVHD includes patients who do not respond adequately to full-dose
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and those who are intolerant or have unacceptable complications with prednisone. We consider any of the following to be SR-cGVHD:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Progressive disease
         </strong>
         despite
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         1 mg/kg/day for two weeks
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stable disease
         </strong>
         after four to six weeks of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ≥0.5 mg/kg/day
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inability to taper
         </strong>
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         to &lt;0.5 mg/kg/day
        </p>
        <p>
        </p>
        <p>
         The definition of SR-cGVHD can vary with the affected organ and clinical manifestations. As an example, skin sclerosis generally requires longer than other cutaneous findings and a shorter period of treatment is warranted if there is significant steroid-associated toxicity [
         <a href="#rid27">
          27,35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3766478165">
         <span class="h2">
          Treatment of SR-cGVHD
         </span>
         <span class="headingEndMark">
          —
         </span>
         When SR-cGVHD is diagnosed in a patient who is already receiving
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         (eg, as prophylaxis for acute GVHD or for treatment of a patient with concurrent acute GVHD/overlap syndrome), we first optimize the dose of the calcineurin inhibitor to ensure a therapeutic level and then reassess the clinical response  (
         <a class="graphic graphic_table graphicRef91020" href="/z/d/graphic/91020.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3543.html" rel="external">
          "Treatment of acute graft-versus-host disease", section on 'Optimizing prophylaxis'
         </a>
         .)
        </p>
        <p>
         For patients with SR-cGVHD, we suggest adding
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         to
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , rather than treating with higher doses of prednisone or adding an alternative second agent (eg, extracorporeal photopheresis [ECP],
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="132098" href="/z/d/drug information/132098.html" rel="external">
          belumosudil
         </a>
         ) to prednisone. Ruxolitinib is generally well-tolerated, and it can achieve a response and reduce steroid use in more than half of patients with SR-cGVHD; a meta-analysis of 329 patients [
         <a href="#rid36">
          36
         </a>
         ] and a phase 3 trial [
         <a href="#rid37">
          37
         </a>
         ] reported that addition of ruxolitinib was superior to addition of best available treatment to prednisone. (See
         <a class="local">
          'Ruxolitinib'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         is not available or is not tolerated, we favor addition of a non-pharmacologic approach, such as ECP or psoralen ultraviolet irradiation (PUVA), where available; these non-pharmacologic treatments can limit or avoid additional adverse effects, but they may be expensive, inconvenient (ie, requiring a large-bore intravenous catheter), or have limited availability.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Otherwise, we choose a second agent according to current medications, toxicity, comorbid conditions, availability, and preferences of the clinician and patient. Alternative second agents are described in the sections that follow.
        </p>
        <p>
        </p>
        <p>
         Patients should be encouraged to enroll on a clinical trial, when possible.
        </p>
        <p class="headingAnchor" id="H3481947149">
         <span class="h3">
          Ruxolitinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          Ruxolitinib
         </a>
         is a selective Janus kinase (JAK) 1/2 inhibitor that interferes with signaling downstream of cytokine receptors. JAK signaling contributes to inflammation and tissue damage in GVHD and ruxolitinib was shown to reduce collagen deposition in preclinical models of pulmonary cGVHD [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          Ruxolitinib
         </a>
         is administered at a dose of 10 mg by mouth, twice daily. For patients with platelets &lt;50,000/microL, the dose of ruxolitinib should be reduced to 5 mg twice daily. Ruxolitinib is contraindicated in patients with platelets &lt;10,000/microL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – Dose adjustments may be required for cytopenias and for renal or hepatic impairment. Toxicity includes cytopenias, liver dysfunction, neurologic complaints, reactivation of viral infections, and bacterial or fungal infections.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A "withdrawal syndrome" that resembles systemic inflammatory response syndrome may be seen when
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         is discontinued in myelofibrosis [
         <a href="#rid39">
          39
         </a>
         ]. Dose reduction should be gradual rather than abrupt, caution is advised to monitor for a withdrawal-like syndrome; resumption of ruxolitinib (and other medical management) may be required in the setting of severe symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         –
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          Ruxolitinib
         </a>
         is effective in achieving an objective response more than half of patients with SR-cGVHD, reducing steroid use, and is generally well-tolerated, based on a systematic review and meta-analysis of 16 cohort studies (414 adults) [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A phase 3 trial of 329 patients with SR-cGVHD reported that
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         achieved superior outcomes and acceptable toxicity, compared with the investigator's choice of best available treatment (BAT) [
         <a href="#rid37">
          37
         </a>
         ]. At week 24, compared with BAT, ruxolitinib achieved superior overall response rate (ORR; 50 versus 26 percent, respectively), improved symptom response (modified Lee symptom score responder rate; 24 versus 11 percent), complete response (CR; 7 versus 3 percent), and median failure-free survival (FFS; 19 versus 6 percent). Ruxolitinib and BAT were associated with comparable rates of grade ≥3 adverse events (AEs) up to week 24 (57 versus 58 percent), including thrombocytopenia (15 versus 10 percent), neutropenia (13 versus 8 percent), and infections: fungal (12 versus 6 percent), viral (34 versus 29 percent), and bacterial (28 versus 26 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Another study reported that treatment with
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         was associated with reduction of steroid dose in 57 percent and 81 percent one-year overall survival (OS) [
         <a href="#rid40">
          40
         </a>
         ]. Other studies reported similar outcomes [
         <a href="#rid41">
          41,42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There is no difference in ORR, OS, and toxicity between adults and children in one study [
         <a href="#rid43">
          43
         </a>
         ]. In another study, 80 percent of children with moderate-severe cGVHD had at least a partial response (PR), including five of seven patients with bronchiolitis obliterans [
         <a href="#rid44">
          44
         </a>
         ]. A retrospective study also reported effectiveness of
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         in children with cGVHD [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1775818624">
         <span class="h3">
          Non-pharmacologic therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Non-pharmacologic therapies can be associated with improvements in cGVHD without adding AEs of additional drugs.
        </p>
        <p class="headingAnchor" id="H673925625">
         <span class="h4">
          Extracorporeal photopheresis
         </span>
         <span class="headingEndMark">
          —
         </span>
         ECP consists of re-infusion of ultraviolet-irradiated autologous peripheral lymphocytes that have been collected by apheresis and incubated with 8-methoxypsoralen [
         <a href="#rid46">
          46-52
         </a>
         ].
        </p>
        <p>
         A literature review identified 735 patients with steroid-resistant, steroid-intolerant, or steroid-dependent cGVHD treated with ECP [
         <a href="#rid53">
          53
         </a>
         ]. ECP resulted in ORRs of 50 to 65 percent (approximately 30 to 35 percent complete) and approximately 25 to 35 percent of patients were able to significantly taper steroid use. Responses were less likely in patients with more extensive disease, those with a history of acute GVHD, and patients with thrombocytopenia.
        </p>
        <p>
         ECP is contraindicated in patients with severe cardiovascular or renal impairment. Immunosuppression results from a decrease in the number and function of circulating lymphocytes due primarily to the inhibition of DNA transcription and mitosis. (See
         <a class="medical medical_review" href="/z/d/html/3543.html" rel="external">
          "Treatment of acute graft-versus-host disease", section on 'Extracorporeal photopheresis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H110870440">
         <span class="h4">
          PUVA (psoralen ultraviolet irradiation)
         </span>
         <span class="headingEndMark">
          —
         </span>
         PUVA combines the administration of psoralens, a class of phototoxic plant-derived compounds, with an exposure to ultraviolet A radiation (UVA) [
         <a href="#rid54">
          54-62
         </a>
         ]. When used in patients with cGVHD and extensive skin involvement, PUVA is usually begun at 25 percent of the normal dose; those with cGVHD and extensive skin involvement may be very sensitive to burning with this modality.
        </p>
        <p>
         In one study, approximately one-third of patients treated with PUVA therapy achieved CR [
         <a href="#rid59">
          59
         </a>
         ]. In some, but not all studies [
         <a href="#rid60">
          60
         </a>
         ], the efficacy of PUVA seemed to be limited to the skin complications of cGVHD, such as a steroid-sparing effect on skin lesions [
         <a href="#rid63">
          63
         </a>
         ]. PUVA may be most effective if used earlier in the course of the disease when GVHD is limited to the skin. (See
         <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">
          "Psoralen plus ultraviolet A (PUVA) photochemotherapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3790134289">
         <span class="h3">
          Calcineurin inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         (CsA) and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         are chemically distinct calcineurin inhibitors that have similar mechanisms of action, clinical efficacy, and AEs. (See
         <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">
          "Pharmacology of cyclosporine and tacrolimus"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – We generally treat with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         1 mg/kg/day plus CsA 6 mg/kg twice daily every other day. We consider
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         (eg, 0.1 mg/kg/day) equally acceptable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Both CsA and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         are associated with hypomagnesemia, hyperkalemia, hypertension, and nephrotoxicity. Other nephrotoxic drugs should be avoided, if possible, so that the agent can be delivered at the target doses. Both agents may cause transplant-associated thrombotic microangiopathy or neurotoxic effects that can necessitate premature discontinuation. (See
         <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">
          "Pharmacology of cyclosporine and tacrolimus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring
         </strong>
         – We adjust dosing based on serum levels. (See
         <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">
          "Pharmacology of cyclosporine and tacrolimus", section on 'Drug monitoring'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – In a trial that randomly assigned 287 patients with severe cGVHD to
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         plus CsA versus prednisone alone, there was no difference in five-year transplant-related mortality (17 versus 13 percent, respectively), OS, recurrent malignancy, need for additional cGVHD therapy, or discontinuation of all immunosuppressive agents [
         <a href="#rid11">
          11
         </a>
         ]. However, patients who received prednisone plus CsA has fewer episodes of avascular necrosis than those treated with prednisone alone (13 versus 22 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Treatment of 61 patients with severe cGVHD using CsA on alternate days with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         was associated with three-year OS was 52 percent, which was superior to historical control patients who were treated with alternate-day prednisone alone (three-year OS 26 percent) [
         <a href="#rid9">
          9
         </a>
         ]. None of the patients treated with CsA/prednisone developed renal failure or required dialysis and most had an excellent performance status (KPS ≥90).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3515323213">
         <span class="h3">
          Belumosudil
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="132098" href="/z/d/drug information/132098.html" rel="external">
          Belumosudil
         </a>
         is an oral inhibitor of ROCK2 (Rho-associated coiled-coil–containing protein kinase 2) that reduces type 17 and follicular helper T cells (by downregulating STAT3) and enhances regulatory T cells (by upregulation of STAT5) [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="132098" href="/z/d/drug information/132098.html" rel="external">
          Belumosudil
         </a>
         is taken 200 mg orally once daily with food. For patients taking a strong CYP3A inducer  (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 4
         </a>
         ) or a proton pump inhibitor, the dose of belumosudil should be increased to 200 mg twice daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – The most common AEs are fatigue, diarrhea, nausea, cough/dyspnea, headache, and elevated liver function tests.
         <a class="drug drug_general" data-topicid="132098" href="/z/d/drug information/132098.html" rel="external">
          Belumosudil
         </a>
         can cause fetal harm.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – A study randomly assigned patients who had two to five prior lines of therapy for cGVHD to
         <a class="drug drug_general" data-topicid="132098" href="/z/d/drug information/132098.html" rel="external">
          belumosudil
         </a>
         200 mg, either once daily (66 patients) or twice daily (66 patients); outcomes and adverse effects were similar with both doses [
         <a href="#rid65">
          65
         </a>
         ]. ORR was 76 percent (including 2 percent CR) and 70 percent had symptomatic improvement (measured by ≥7 point reduction in the Lee Symptom Scale [LSS]). Belumosudil was well tolerated; the most common grade ≥3 AEs were pneumonia (7 percent), hypertension (6 percent), and hyperglycemia (5 percent).
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="132098" href="/z/d/drug information/132098.html" rel="external">
          Belumosudil
         </a>
         is approved by the US Food and Drug Administration (FDA) for patients ≥12 years with cGVHD after failure of ≥2 prior lines of systemic therapy.
        </p>
        <p class="headingAnchor" id="H1939407345">
         <span class="h3">
          Ibrutinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          Ibrutinib
         </a>
         is an inhibitor of Bruton's tyrosine kinase (BTK) that has activity against cGVHD.
        </p>
        <p>
         A phase 2 study of
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         in 42 patients with SR-cGVHD reported responses in two-thirds (one-third with CR) [
         <a href="#rid66">
          66
         </a>
         ]. Improvement occurred in multiple organ systems (eg, skin, mouth, gastrointestinal tract, liver) and responses lasted ≥5 months in half of patients. Response to ibrutinib permitted reduction of glucocorticoid dose to ≤0.15 mg/kg/day in nearly two-thirds and was associated with improved quality of life. Common AEs in patients with cGVHD included fatigue, bruising, stomatitis, nausea, diarrhea, thrombocytopenia, and anemia; more serious AEs included hemorrhage, infections, atrial fibrillation, hypertension, and tumor lysis syndrome.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          Ibrutinib
         </a>
         is approved by the US FDA for treatment of cGVHD [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3197561795">
         <span class="h3">
          Other second agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following agents can be considered when cGVHD has proven refractory to
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         plus an agent described above. Selection is based on toxicity, adverse effects, and availability, as there are no direct comparisons of efficacy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mycophenolate
         </strong>
         <strong>
          mofetil
         </strong>
         (MMF) is an immunosuppressive agent that has antibacterial, antifungal, antiviral, and antitumor properties.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Administration
         </strong>
         – We generally treat with MMF 1 to 1.5 g (15 mg/kg) twice daily in combination with cyclosporin or
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Toxicity
         </strong>
         – AEs at commonly employed doses have been low; neutropenia is the most common AE, but gastrointestinal side effects have also been reported.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Outcomes
         </strong>
         – Addition of MMF (2 g daily) to
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         and
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         was evaluated in a single center trial of 24 patients with GVHD, including seven patients with chronic GVHD [
         <a href="#rid68">
          68
         </a>
         ]. Moderate improvement in symptoms was seen in three of six patients with limited stage chronic GVHD. The most common toxicities were leukopenia, anemia, and thrombocytopenia.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         A phase 3 trial of 230 patients was terminated after four years because an interim analysis indicated a low probability that
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         plus MMF was better than prednisone plus placebo for controlling cGVHD and enabling withdrawal of all systemic treatment [
         <a href="#rid12">
          12
         </a>
         ]. Addition of MMF had no effect on the amount of prednisone treatment or the proportion of patients with CRs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sirolimus
         </strong>
         (rapamycin) has been used for the treatment of SR-cGVHD [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There is no standard dose, but a reasonable regimen is a loading dose of 6 mg followed by a daily dose of 2 mg, aiming for a target serum level of 10 ng/microL. Common toxicities include hyperlipidemia, renal dysfunction, and cytopenias; thrombotic microangiopathies, infectious complications, and seizures are also reported.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          Sirolimus
         </a>
         has also been associated with sinusoidal obstruction syndrome (SOS; also called hepatic veno-occlusive disease [VOD]) following myeloablative conditioning regimens (especially with
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         conditioning). (See
         <a class="medical medical_review" href="/z/d/html/129806.html" rel="external">
          "Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults", section on 'Aspects of transplantation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Treatment of 35 patients with SR-cGVHD with
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         plus
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         and
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         was associated with 63 percent overall response (17 percent CR) [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rituximab
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         (375 mg/m
         <sup>
          2
         </sup>
         intravenously) is administered weekly for four weeks; if there is at least a PR, up to two more four-week courses may be administered.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Toxicity
         </strong>
         –
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         can be associated with re-activation of hepatitis B. (See
         <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">
          "Hepatitis B virus reactivation associated with immunosuppressive therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Outcomes
         </strong>
         –
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         appears to be especially beneficial for patients with skin, oral, or musculoskeletal involvement.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Clinical responses were reported in 86 percent of 37 patients with SR-cGVHD and most responses were maintained at one year, with reductions of glucocorticoid dose in 57 percent of patients [
         <a href="#rid70">
          70
         </a>
         ]. Other studies also report comparable patterns of response [
         <a href="#rid70">
          70-76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tyrosine kinase inhibitors
         </strong>
         – Small prospective and retrospective studies have evaluated the use of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , a tyrosine kinase inhibitor (TKI), for patients with cGVHD [
         <a href="#rid77">
          77-80
         </a>
         ]. In three prospective studies performed in patients with SR-cGVHD, responses were seen in 7 of 14 patients, 15 of 19 patients, and 20 of 39 patients, respectively [
         <a href="#rid77">
          77,78,80
         </a>
         ]. While CRs were not seen, many patients are able to decrease their steroid requirements. This agent has also had some effectiveness in patients with cGVHD involving the lungs [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A phase 2 study reported improvement in skin sclerosis or joint range of motion in one-third of 35 patients treated with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bortezomib
         </strong>
         is a proteasome inhibitor that has activity in cGVHD. A phase 2 study of
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         (1.3 mg/m
         <sup>
          2
         </sup>
         intravenously on days 1, 8, 15, and 22 of each 35-day cycle for 3 cycles) plus
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (0.5 to 1 mg/kg/day, with taper after cycle 1) as initial treatment for cGVHD in 22 patients reported 80 percent ORR at 15 weeks (10 percent CR) [
         <a href="#rid82">
          82
         </a>
         ]. Organ-specific CR was 73 percent for skin, 53 percent for liver, 75 percent for gastrointestinal tract, and 33 percent for joint, muscle, or fascia involvement [
         <a href="#rid82">
          82
         </a>
         ]. Treatment was well-tolerated, with one occurrence of grade 3 sensory peripheral neuropathy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interleukin-2
         </strong>
         (IL-2) may produce responses in SR-cGVHD, but we await further study before incorporating it into routine care. IL-2 is a T cell-derived cytokine that plays a central role in immune responses and the development and function of regulatory T cells (Tregs). Animal studies that suggested that Treg cells could control GVHD and that IL-2 depletion by calcineurin inhibition reduced Treg activity [
         <a href="#rid83">
          83
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3545.html" rel="external">
          "Pathogenesis of graft-versus-host disease (GVHD)", section on 'Overview of GVHD'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A phase 2 study of IL-2 (1x10
         <sup>
          6
         </sup>
         international units/m
         <sup>
          2
         </sup>
         ) in 35 adults with SR-cGVHD reported clinical responses in 20 of 33 evaluable patients (none complete) by week 12; 10 patients had stable disease and three had progressive disease [
         <a href="#rid84">
          84
         </a>
         ]. AEs resulted in dose reduction in five patients and early withdrawal in two.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other agents
         </strong>
         that have been used to treat SR-cGVHD include
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         [
         <a href="#rid85">
          85
         </a>
         ],
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         [
         <a href="#rid86">
          86,87
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9756" href="/z/d/drug information/9756.html" rel="external">
          pentostatin
         </a>
         [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2519422875">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of severe cGVHD, overlap syndrome, and extensive skin disease are associated with adverse outcomes; thrombocytopenia was also associated with inferior outcomes in some studies [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Moderate/severe cGVHD
         </strong>
         – Involvement of ≥3 organs or involvement of any single organ with severity score &gt;2  (
         <a class="graphic graphic_form graphicRef69017" href="/z/d/graphic/69017.html" rel="external">
          form 1
         </a>
         ) is associated with greater morbidity and inferior survival, compared with mild disease [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overlap syndrome
         </strong>
         – The prognostic importance of overlap syndrome is uncertain. A study using the National Institutes of Health (NIH) severity grading criteria reported that outcomes with overlap syndrome were inferior to classic cGVHD [
         <a href="#rid90">
          90
         </a>
         ]; older studies also identified "progressive onset" (which largely comprised overlap syndrome) as associated with adverse outcomes [
         <a href="#rid91">
          91-93
         </a>
         ]. In contrast, a retrospective study found no difference in overall survival (OS) between overlap syndrome and cGVHD [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extensive skin involvement
         </strong>
         – Skin involvement &gt;50 percent body surface area (BSA) has been associated with poor outcomes [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thrombocytopenia
         </strong>
         – In some studies, thrombocytopenia (&lt;100,000/microL) was associated with inferior outcomes, but this may be limited to patients who were transplanted using myeloablative conditioning and peripheral blood stem cells as a graft source [
         <a href="#rid8">
          8,9,89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3117081372">
         <span class="h1">
          CLINICAL TRIALS
         </span>
         <span class="headingEndMark">
          —
         </span>
         We strongly encourage participation in a clinical trial, when available. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=3550" target="_blank">
          clinicaltrials.gov
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3113104">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chronic graft-versus-host disease (cGVHD)
         </strong>
         is the major determinant of long-term outcome and quality of life following allogeneic hematopoietic cell transplantation (HCT). The primary manifestations of cGVHD are sclerotic cutaneous effects, dry oral mucosa, ulcerations and sclerosis of the gastrointestinal tract, and elevated serum bilirubin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinical manifestations, diagnosis, and grading of cGVHD are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">
          "Clinical manifestations and diagnosis of chronic graft-versus-host disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Grading
         </strong>
         is according to our modification of the National Institutes of Health (NIH) GVHD scoring system  (
         <a class="graphic graphic_form graphicRef69017" href="/z/d/graphic/69017.html" rel="external">
          form 1
         </a>
         ), which surveys symptoms, affected organ systems, and severity and extent of involvement (graded 0 to 3). There are no validated biomarkers for cGVHD severity. We classify cGVHD as:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mild
         </strong>
         – ≤2 affected organs, no pulmonary manifestations, Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2 (see
         <a class="local">
          'Mild cGVHD'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Moderate
         </strong>
         – Involvement of ≥3 organs with score ≤1, lung score 1, any non-lung organ score 2, or ECOG PS ≥3 (see
         <a class="local">
          'Moderate cGVHD'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Severe
         </strong>
         – Lung score ≥2, any non-lung score 3, or &lt;100,000 platelets/microL (see
         <a class="local">
          'Severe cGVHD'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         is based on disease severity, scored with the modified NIH scale  (
         <a class="graphic graphic_algorithm graphicRef132572" href="/z/d/graphic/132572.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mild cGVHD
         </strong>
         – For patients with mild cGVHD, we suggest localized or topical treatment rather than systemic therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), to avoid adverse effects (AEs)/complications of systemic
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and other systemic immunosuppressive agents. (See
         <a class="local">
          'Mild cGVHD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Localized or topical therapy varies according to the affected organ, as described above. (See
         <a class="local">
          'Localized/topical treatments'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Moderate cGVHD
         </strong>
         – For initial treatment of moderate cGVHD, we recommend systemic
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , rather than an alternative immunosuppressive agent, either alone or together with prednisone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Moderate cGVHD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Topical therapy can be added to systemic
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , if needed, to ameliorate localized symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Severe cGVHD –
         </strong>
         For initial treatment of severe cGVHD, we suggest
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         plus
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         , rather than prednisone alone or prednisone plus another second agent (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Severe cGVHD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Response assessment
         </strong>
         is performed according to the NIH Consensus Criteria for Clinical Trials in cGVHD. (See
         <a class="local">
          'Response assessment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Steroid-refractory (SR) cGVHD
         </strong>
         – For patients with SR-cGVHD, we recommend addition of
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         to
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , rather than addition of other systemic medications (eg,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         ) or non-pharmacologic approaches (eg, extracorporeal photopheresis, psoralen ultraviolet irradiation therapy) to prednisone (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ).
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arora M, Cutler CS, Jagasia MH, et al. Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2016; 22:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015; 21:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006; 12:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dignan FL, Amrolia P, Clark A, et al. Diagnosis and management of chronic graft-versus-host disease. Br J Haematol 2012; 158:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dignan FL, Scarisbrick JJ, Cornish J, et al. Organ-specific management and supportive care in chronic graft-versus-host disease. Br J Haematol 2012; 158:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol 2020; 7:e157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 1988; 72:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koc S, Leisenring W, Flowers ME, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002; 100:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin PJ, Storer BE, Rowley SD, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood 2009; 113:5074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arora M, Wagner JE, Davies SM, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001; 7:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koc S, Leisenring W, Flowers ME, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000; 96:3995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilman AL, Schultz KR, Goldman FD, et al. Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study. Biol Blood Marrow Transplant 2012; 18:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miklos DB, Abu Zaid M, Cooney JP, et al. Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study. J Clin Oncol 2023; 41:1876.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hildebrandt GC, Fazekas T, Lawitschka A, et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant 2011; 46:1283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marks C, Stadler M, Häusermann P, et al. German-Austrian-Swiss Consensus Conference on clinical practice in chronic graft-versus-host disease (GVHD): guidance for supportive therapy of chronic cutaneous and musculoskeletal GVHD. Br J Dermatol 2011; 165:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frey Tirri B, Häusermann P, Bertz H, et al. Clinical guidelines for gynecologic care after hematopoietic SCT. Report from the international consensus project on clinical practice in chronic GVHD. Bone Marrow Transplant 2015; 50:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mays JW, Fassil H, Edwards DA, et al. Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research. Oral Dis 2013; 19:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dietrich-Ntoukas T, Cursiefen C, Westekemper H, et al. Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD. Cornea 2012; 31:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jung JW, Lee YJ, Yoon SC, et al. Long-term result of maintenance treatment with tacrolimus ointment in chronic ocular graft-versus-host disease. Am J Ophthalmol 2015; 159:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsch P, Leclerc M, Rybojad M, et al. Female genital chronic graft-versus-host disease: importance of early diagnosis to avoid severe complications. Transplantation 2012; 93:1265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobson M, Wong J, Li A, Wolfman WL. Vulvovaginal graft-versus-host disease: a review. Climacteric 2019; 22:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mielcarek M, Storer BE, Boeckh M, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009; 113:2888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolff D, Gerbitz A, Ayuk F, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010; 16:1611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Axt L, Naumann A, Toennies J, et al. Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2019; 54:1805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flowers ME, Storer B, Carpenter P, et al. Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14:1380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inamoto Y, Flowers ME, Sandmaier BM, et al. Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. Blood 2014; 124:1363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pavletic SZ, Martin P, Lee SJ, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006; 12:252.
          </a>
         </li>
         <li class="breakAll">
          http://c.ymcdn.com/sites/asbmt.site-ym.com/resource/resmgr/Docs/ResponseCriteriaAPPENDIXAFor.pdf (Accessed on June 26, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmer J, Chai X, Pidala J, et al. Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. Blood 2016; 127:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin PJ, Weisdorf D, Przepiorka D, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant 2006; 12:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hui L, Qi L, Guoyu H, et al. Ruxolitinib for treatment of steroid-refractory graft-versus-host disease in adults: a systematic review and meta-analysis. Expert Rev Hematol 2020; 13:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeiser R, Polverelli N, Ram R, et al. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. N Engl J Med 2021; 385:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 2015; 29:2062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011; 86:1188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Escamilla Gómez V, García-Gutiérrez V, López Corral L, et al. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. Bone Marrow Transplant 2020; 55:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Modi B, Hernandez-Henderson M, Yang D, et al. Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 2019; 25:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu H, Shi J, Luo Y, et al. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. JAMA Netw Open 2021; 4:e2034750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moiseev IS, Morozova EV, Bykova TA, et al. Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults. Bone Marrow Transplant 2020; 55:1379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uygun V, Karasu G, Daloğlu H, et al. Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience. Pediatr Blood Cancer 2020; 67:e28190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang W, Zhu G, Qin M, et al. The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study. Drug Des Devel Ther 2021; 15:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greinix HT, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92:3098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alcindor T, Gorgun G, Miller KB, et al. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood 2001; 98:1622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dall'Amico R, Messina C. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher 2002; 6:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Messina C, Locatelli F, Lanino E, et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003; 122:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seaton ED, Szydlo RM, Kanfer E, et al. Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood 2003; 102:1217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubegni P, Cuccia A, Sbano P, et al. Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. Br J Haematol 2005; 130:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dignan FL, Aguilar S, Scarisbrick JJ, et al. Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD. Bone Marrow Transplant 2014; 49:704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierelli L, Perseghin P, Marchetti M, et al. Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process. Transfusion 2013; 53:2340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hymes SR, Morison WL, Farmer ER, et al. Methoxsalen and ultraviolet A radiation in treatment of chronic cutaneous graft-versus-host reaction. J Am Acad Dermatol 1985; 12:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atkinson K, Weller P, Ryman W, Biggs J. PUVA therapy for drug-resistant graft-versus-host disease. Bone Marrow Transplant 1986; 1:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deeg HJ. Ultraviolet irradiation in transplantation biology. Manipulation of immunity and immunogenicity. Transplantation 1988; 45:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eppinger T, Ehninger G, Steinert M, et al. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation 1990; 50:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kripke ML. Immunological unresponsiveness induced by ultraviolet radiation. Immunol Rev 1984; 80:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kapoor N, Pelligrini AE, Copelan EA, et al. Psoralen plus ultraviolet A (PUVA) in the treatment of chronic graft versus host disease: preliminary experience in standard treatment resistant patients. Semin Hematol 1992; 29:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006; 107:3074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall SR. Technology insight: ECP for the treatment of GvHD--can we offer selective immune control without generalized immunosuppression? Nat Clin Pract Oncol 2006; 3:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knobler R, Barr ML, Couriel DR, et al. Extracorporeal photopheresis: past, present, and future. J Am Acad Dermatol 2009; 61:652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008; 112:2667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A 2014; 111:16814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cutler C, Lee SJ, Arai S, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood 2021; 138:2278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood 2017; 130:2243.
          </a>
         </li>
         <li class="breakAll">
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205552s017lbl.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basara N, Blau WI, Römer E, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998; 22:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Couriel DR, Saliba R, Escalón MP, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 2005; 130:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SJ, Lee JW, Jung CW, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica 2010; 95:1935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000; 133:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2004; 104:2603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alousi AM, Uberti J, Ratanatharathorn V. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. Leuk Lymphoma 2010; 51:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clavert A, Chevallier P, Guillaume T, et al. Safety and efficacy of rituximab in steroid-refractory chronic GVHD. Bone Marrow Transplant 2013; 48:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arai S, Pidala J, Pusic I, et al. A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clin Cancer Res 2016; 22:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magro L, Mohty M, Catteau B, et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009; 114:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009; 114:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Masson A, Bouaziz JD, Peffault de Latour R, et al. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. Blood 2012; 120:5089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olivieri A, Cimminiello M, Corradini P, et al. Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood 2013; 122:4111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stadler M, Ahlborn R, Kamal H, et al. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease. Blood 2009; 114:3718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrera AF, Kim HT, Bindra B, et al. A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2014; 20:1737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koreth J, Kim HT, Jones KT, et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood 2016; 128:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiang KY, Abhyankar S, Bridges K, et al. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002; 73:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992; 326:1055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 86:3604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobsohn DA, Chen AR, Zahurak M, et al. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol 2007; 25:4255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akpek G, Zahurak ML, Piantadosi S, et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001; 97:1219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jagasia M, Giglia J, Chinratanalab W, et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant 2007; 13:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989; 74:1428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arora M, Nagaraj S, Witte J, et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant 2009; 43:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cho BS, Min CK, Eom KS, et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia 2009; 23:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vigorito AC, Campregher PV, Storer BE, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009; 114:702.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3550 Version 53.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16338616" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26541363" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25529383" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16545722" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22533811" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Diagnosis and management of chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22533889" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Organ-specific management and supportive care in chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32004485" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3042041" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3042042" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7004534" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12070007" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19270260" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11400948" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11090092" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Thalidomide for treatment of patients with chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21689773" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36608310" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12091329" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21441964" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21466534" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : German-Austrian-Swiss Consensus Conference on clinical practice in chronic graft-versus-host disease (GVHD): guidance for supportive therapy of chronic cutaneous and musculoskeletal GVHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25347009" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Clinical guidelines for gynecologic care after hematopoietic SCT. Report from the international consensus project on clinical practice in chronic GVHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23107104" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22157574" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25498356" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Long-term result of maintenance treatment with tacrolimus ointment in chronic ocular graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22466789" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Female genital chronic graft-versus-host disease: importance of early diagnosis to avoid severe complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31315476" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Vulvovaginal graft-versus-host disease: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19001082" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20601036" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12720215" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31089279" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19041060" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24876566" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Failure-free survival after initial systemic treatment of chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16503494" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16503494" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26527676" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16635784" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32178541" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Ruxolitinib for treatment of steroid-refractory graft-versus-host disease in adults: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34260836" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26228813" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22034658" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31700138" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30201397" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33502484" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32071418" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31981413" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33654380" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9787144" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11520818" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12164800" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Extracorporeal photochemotherapy for the treatment of graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12823353" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12714516" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16029456" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24566709" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23305044" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3980801" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Methoxsalen and ultraviolet A radiation in treatment of chronic cutaneous graft-versus-host reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3502781" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : PUVA therapy for drug-resistant graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3285528" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Ultraviolet irradiation in transplantation biology. Manipulation of immunity and immunogenicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2238056" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6237978" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Immunological unresponsiveness induced by ultraviolet radiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1594942" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Psoralen plus ultraviolet A (PUVA) in the treatment of chronic graft versus host disease: preliminary experience in standard treatment resistant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16368882" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16757968" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Technology insight: ECP for the treatment of GvHD--can we offer selective immune control without generalized immunosuppression?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19665258" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Extracorporeal photopheresis: past, present, and future.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18621929" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25385601" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34265047" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28924018" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28924018" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9678797" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16042691" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20663943" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10929168" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15251978" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16551963" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Rituximab for steroid-refractory chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20141428" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23085828" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Safety and efficacy of rituximab in steroid-refractory chronic GVHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26378033" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19289852" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19403889" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Imatinib for refractory chronic graft-versus-host disease with fibrotic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23243159" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24152907" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19850751" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25017765" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16522809" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27073224" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11889452" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1549151" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Thalidomide for the treatment of chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7579470" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Thalidomide as salvage therapy for chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17878478" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11222363" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Development of a prognostic model for grading chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17889358" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2670000" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Predictors of death from chronic graft-versus-host disease after bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18794869" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : New classification of chronic GVHD: added clarity from the consensus diagnoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18830253" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Feasibility of NIH consensus criteria for chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19470693" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
